Developing a new adjuvant for malaria vaccines
Official title: A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
Funded at Columbia University Health Sciences · NIH-11127342 · Data updated 2026-11-12
This study is testing a new ingredient called 7DW8-5 that could make malaria vaccines work better, and it's aimed at helping people who need more effective and easier-to-use vaccines.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 30, 2023 |
| Project end | September 29, 2028 |
| Funding year | 2024 |
| Award (this year) | $1,089,350 |
| NIH project number | 75N93023C00041-P00001-9999-1 |
| Project ID | NIH-11127342 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of malaria, particularly those living in endemic regions.
✕Less likely to help
Patients who are not at risk of malaria or those who have already been vaccinated against malaria may not receive any benefit from this research.
What this research studies
This research focuses on creating a glycolipid-based adjuvant called 7DW8-5 to enhance the effectiveness of malaria vaccines. The approach involves using a novel compound that stimulates natural killer T cells, which are crucial for immune response. The research will evaluate the adjuvant's formulation, stability, and safety in both laboratory settings and non-human primates before moving towards regulatory approval for human use. Patients may benefit from improved malaria vaccines that are more effective and easier to administer.
Why it matters
Potential benefit: If successful, this research could lead to more effective malaria vaccines, potentially reducing the incidence of malaria in affected populations.
How similar studies have gone: Previous research has shown success with similar adjuvant approaches in enhancing vaccine efficacy, indicating a promising avenue for malaria vaccine development.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Tsuji, Moriya — Columbia University Health Sciences
- Study coordinator: Tsuji, Moriya
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Malaria control project in Western Kenya to reduce illness and deaths
A large, multi-year effort in western Kenya will help track malaria spread and test ways to prevent transmission so fewer people get sick or die.
-
Optimizing tafenoquine dose to prevent relapse of vivax malaria in Asia
A study tests the best tafenoquine dose to prevent P. vivax malaria relapse in people in East Asia and Oceania.
-
Optimizing tafenoquine dose to prevent P. vivax malaria relapses in Asia
A study to find the best single-dose tafenoquine amount to prevent relapse of P. vivax malaria in people in East Asia and Oceania.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.